This study examines how gut microbiome can affect cancer therapy in cancer patients undergoing cancer therapy or stem cell transplant. The human microbiome affects the way some cancer drugs are metabolized in the human body. Information from this study may help doctors improve the way cancer treatment is delivered, and increase its effectiveness and success.
PRIMARY OBJECTIVE: I. To correlate gut microbiome with specific cancer diagnoses and the clinical response (efficacy), and adverse effects of cancer therapy (single or multiple) and stem cell transplant. OUTLINE: Patients undergo collection of blood and stool samples and have their medical records reviewed.
Study Type
OBSERVATIONAL
Enrollment
3,000
Undergo collection of blood and stool samples
Review of medical records
Mayo Clinic in Arizona
Scottsdale, Arizona, United States
ACTIVE_NOT_RECRUITINGMayo Clinic in Florida
Jacksonville, Florida, United States
ACTIVE_NOT_RECRUITINGMayo Clinic in Rochester
Rochester, Minnesota, United States
RECRUITINGGut microbiome associations with cancer diagnoses
Will be done using Shogun pipeline for metagenomics data followed by analysis using Quantitative Insights Into Microbial Ecology (QIIME) 2.0.
Time frame: Through study completion, average of 1 year
Associations between microbial community abundances and clinical outcomes
Will use a linear multivariate regression model specifically developed for microbiome data (MaAsLin, Multivariate microbial Association by Linear models.
Time frame: Through study completion, average of 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.